Medizinische Universität Graz - Research portal
Selected Publication:
Pummer, K; Lehnert, M; Seewann, HL.
Chemohormonal and immunohormonal approaches in advanced prostatic carcinoma.
Eur Urol. 1993; 24 Suppl 2(3A):81-86
Doi: 10.1159/000474397
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Pummer Karl
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The standard palliative treatment for patients with advanced prostate cancer has for the past 50 years been androgen withdrawal. However, owing to the presence of hormone-insensitive cell clones, the benefits of this approach have now appeared to reach their optimum. It is now generally believed that further major therapeutic advances in the treatment of prostate cancer are unlikely, unless consideration is given to these hormonally independent cells. Two possible alternative strategies which address this problem are chemohormonal and immunohormonal approaches, both of which are discussed in detail in this article.
- Find related publications in this database (using NLM MeSH Indexing)
- Androgen Antagonists - therapeutic use
- Antineoplastic Agents - therapeutic use
- Combined Modality Therapy - therapeutic use
- Humans - therapeutic use
- Interferons - therapeutic use
- Male - therapeutic use
- Neoplasm Metastasis - therapeutic use
- Prostatic Neoplasms - pathology
- Find related publications in this database (Keywords)
- Chemohormonal Therapy
- Immunohormonal Therapy
- Prostate Cancer
- Carcinoma
- Prostatic
- Interferons
- Chemotherapy
- Flutamide
- Androgen Blockade
- Total